Core Viewpoint - The company expects to achieve significant revenue growth and profitability by the end of 2025, driven by new product launches and increased sales in various medical segments [1] Financial Performance - The company projects revenue of approximately 400 million to 410 million yuan for the year ending December 31, 2025, representing an increase of at least 43.9% compared to the revenue of 278 million yuan for the year ending December 31, 2024 [1] - The expected pre-tax profit is around 80 million yuan, a substantial improvement from the pre-tax net loss of 12 million yuan for the year ending December 31, 2024 [1] Growth Drivers - The turnaround from loss to profit is primarily attributed to the launch of new products and technologies for ischemic stroke, the commercialization of intracranial stents, increased sales of other hemorrhagic stroke products, and sustained growth in interventional pathway product sales [1]
心玮医疗：预计2025年收益约4亿元至4.1亿元，转亏为盈主要因多款产品销售增长